Now showing items 1-20 of 207

    • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. 

      Cameron, D; Piccart-Gebhart, MJ; Gelber, RD; Procter, M; Goldhirsch, A; de Azambuja, E; Castro, G; Untch, M; Smith, I; Gianni, L; Baselga, J; Al-Sakaff, N; Lauer, S; McFadden, E; Leyland-Jones, B; Bell, R; Dowsett, M; Jackisch, C; Herceptin Adjuvant (HERA) Trial Study Team
      BACKGROUND: Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast ...
    • 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. 

      Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; McGale, P; Peto, R; Pritchard, KI; Bergh, J; Dowsett, M; Hayes, DF; EBCTCG
      BACKGROUND: The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such ...
    • 3D modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. 

      Maguire, SL; Peck, B; Wai, PT; Campbell, J; Barker, H; Gulati, A; Daley, F; Vyse, S; Huang, P; Lord, CJ; Farnie, G; Brennan, K; Natrajan, R (2016-08-11)
      The initiation and progression of breast cancer from the transformation of the normal epithelium to ductal carcinoma in situ (DCIS) and invasive disease is a complex process involving the acquisition of genetic alterations, ...
    • Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breast. 

      Naidoo, K; Beardsley, B; Carder, PJ; Deb, R; Fish, D; Girling, A; Hales, S; Howe, M; Wastall, LM; Lane, S; Lee, AHS; Philippidou, M; Quinn, C; Stephenson, T; Pinder, SE (2016-12)
      Although the UK National Institute for Health and Care Excellence guidelines recommend that in patients with biopsy-proven invasive lobular carcinoma (ILC), preoperative MRI scan is considered, the accuracy of diagnosis ...
    • Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN. 

      Fowler, A; Mahamdallie, S; Ruark, E; Seal, S; Ramsay, E; Clarke, M; Uddin, I; Wylie, H; Strydom, A; Lunter, G; Rahman, N (2016-11-25)
      Background: Targeted next generation sequencing (NGS) panels are increasingly being used in clinical genomics to increase capacity, throughput and affordability of gene testing. Identifying whole exon deletions or duplications ...
    • Advances and challenges in targeting FGFR signalling in cancer. 

      Babina, IS; Turner, NC
      Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Deregulation of FGFR signalling is observed in a subset of many cancers, making activated FGFRs a highly promising potential ...
    • Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. 

      Turner, NC; Neven, P; Loibl, S; Andre, F (2017-06-17)
      Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development ...
    • Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. 

      Turner, NC; Neven, P; Loibl, S; Andre, F (2017-06-17)
      Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development ...
    • AnIn VivoFunctional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer. 

      Ashenden, M; van Weverwijk, A; Murugaesu, N; Fearns, A; Campbell, J; Gao, Q; Iravani, M; Isacke, CM (2017-09)
      Chemotherapy remains the mainstay of treatment for advanced breast cancer; however, resistance is an inevitable event for the majority of patients with metastatic disease. Moreover, there is little information available ...
    • Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. 

      Zhao, Z; Wen, W; Michailidou, K; Bolla, MK; Wang, Q; Zhang, B; Long, J; Shu, XO; Schmidt, MK; Milne, RL; García-Closas, M; Chang-Claude, J; Lindstrom, S; Bojesen, SE; Ahsan, H; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Beeghly-Fadiel, A; Benitez, J; Blomqvist, C; Bogdanova, NV; Børresen-Dale, AL; Brand, J; Brauch, H; Brenner, H; Burwinkel, B; Cai, Q; Casey, G; Chenevix-Trench, G; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dörk, T; Dumont, M; Fasching, PA; Figueroa, J; Flesch-Janys, D; Fletcher, O; Flyger, H; Fostira, F; Gammon, M; Giles, GG; Guénel, P; Haiman, CA; Hamann, U; Harrington, P; Hartman, M; Hooning, MJ; Hopper, JL; Jakubowska, A; Jasmine, F; John, EM; Johnson, N; Kabisch, M; Khan, S; Kibriya, M; Knight, JA; Kosma, VM; Kriege, M; Kristensen, V; Le Marchand, L; Lee, E; Li, J; Lindblom, A; Lophatananon, A; Luben, R; Lubinski, J; Malone, KE; Mannermaa, A; Manoukian, S; Margolin, S; Marme, F; McLean, C; Meijers-Heijboer, H; Meindl, A; Miao, H; Muir, K; Neuhausen, SL; Nevanlinna, H; Neven, P; Olson, JE; Perkins, B; Peterlongo, P; Phillips, KA; Pylkäs, K; Rudolph, A; Santella, R; Sawyer, EJ; Schmutzler, RK; Schoemaker, M; Shah, M; Shrubsole, M; Southey, MC; Swerdlow, AJ; Toland, AE; Tomlinson, I; Torres, D; Truong, T; Ursin, G; Van Der Luijt, RB; Verhoef, S; Wang-Gohrke, S; Whittemore, AS; Winqvist, R; Pilar Zamora, M; Zhao, H; Dunning, AM; Simard, J; Hall, P; Kraft, P; Pharoah, P; Hunter, D; Easton, DF; Zheng, W (2016-05)
      Type 2 diabetes (T2D) has been reported to be associated with an elevated risk of breast cancer. It is unclear, however, whether this association is due to shared genetic factors.We constructed a genetic risk score (GRS) ...
    • ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. 

      Williamson, CT; Miller, R; Pemberton, HN; Jones, SE; Campbell, J; Konde, A; Badham, N; Rafiq, R; Brough, R; Gulati, A; Ryan, CJ; Francis, J; Vermulen, PB; Reynolds, AR; Reaper, PM; Pollard, JR; Ashworth, A; Lord, CJ (2016-12-13)
      Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one approach to the development of targeted cancer therapies. Mutations in ARID1A represent one of the most common molecular alterations ...
    • ATR Is a Therapeutic Target in Synovial Sarcoma. 

      Jones, SE; Fleuren, EDG; Frankum, J; Konde, A; Williamson, CT; Krastev, DB; Pemberton, HN; Campbell, J; Gulati, A; Elliott, R; Menon, M; Selfe, JL; Brough, R; Pettitt, SJ; Niedzwiedz, W; van der Graaf, WTA; Shipley, J; Ashworth, A; Lord, CJ
      Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18-SSX fusions, where treatment options are limited. To identify therapeutically actionable genetic dependencies in SS, we ...
    • Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosis. 

      Gurden, MD; Anderhub, SJ; Faisal, A; Linardopoulos, S (2016-07-18)
      Accurate chromosome segregation is dependent on the spindle assembly checkpoint (SAC). In current models, the key direct role of Aurora B in the SAC has been suggested to be to promote rapid kinetochore localisation of ...
    • Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation. 

      Yost, S; de Wolf, B; Hanks, S; Zachariou, A; Marcozzi, C; Clarke, M; de Voer, R; Etemad, B; Uijttewaal, E; Ramsay, E; Wylie, H; Elliott, A; Picton, S; Smith, A; Smithson, S; Seal, S; Ruark, E; Houge, G; Pines, J; Kops, GJPL; Rahman, N (2017-07)
      Through exome sequencing, we identified six individuals with biallelic loss-of-function mutations in TRIP13. All six developed Wilms tumor. Constitutional mosaic aneuploidies, microcephaly, developmental delay and seizures, ...
    • Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. 

      Bianchini, G; Kiermaier, A; Bianchi, GV; Im, Y-H; Pienkowski, T; Liu, M-C; Tseng, L-M; Dowsett, M; Zabaglo, L; Kirk, S; Szado, T; Eng-Wong, J; Amler, LC; Valagussa, P; Gianni, L (2017-02-09)
      BACKGROUND: NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab ...
    • BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. 

      Shimelis, H; Mesman, RLS; Von Nicolai, C; Ehlen, A; Guidugli, L; Martin, C; Calléja, FMGR; Meeks, H; Hallberg, E; Hinton, J; Lilyquist, J; Hu, C; Aalfs, CM; Aittomäki, K; Andrulis, I; Anton-Culver, H; Arndt, V; Beckmann, MW; Benitez, J; Bogdanova, NV; Bojesen, SE; Bolla, MK; Borresen-Dale, A-L; Brauch, H; Brennan, P; Brenner, H; Broeks, A; Brouwers, B; Brüning, T; Burwinkel, B; Chang-Claude, J; Chenevix-Trench, G; Cheng, C-Y; Choi, J-Y; Collée, JM; Cox, A; Cross, SS; Czene, K; Darabi, H; Dennis, J; Dörk, T; Dos-Santos-Silva, I; Dunning, AM; Fasching, PA; Figueroa, J; Flyger, H; García-Closas, M; Giles, GG; Glendon, G; Guénel, P; Haiman, CA; Hall, P; Hamann, U; Hartman, M; Hogervorst, FB; Hollestelle, A; Hopper, JL; Ito, H; Jakubowska, A; Kang, D; Kosma, V-M; Kristensen, V; Lai, K-N; Lambrechts, D; Marchand, LL; Li, J; Lindblom, A; Lophatananon, A; Lubinski, J; Machackova, E; Mannermaa, A; Margolin, S; Marme, F; Matsuo, K; Miao, H; Michailidou, K; Milne, RL; Muir, K; Neuhausen, SL; Nevanlinna, H; Olson, JE; Olswold, C; Oosterwijk, JJC; Osorio, A; Peterlongo, P; Peto, J; Pharoah, PDP; Pylkäs, K; Radice, P; Rashid, MU; Rhenius, V; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schoemaker, MJ; Seynaeve, C; Shah, M; Shen, C-Y; Shrubsole, M; Shu, X-O; Slager, S; Southey, MC; Stram, DO; Swerdlow, A; Teo, SH; Tomlinson, I; Torres, D; Truong, T; van Asperen, CJ; van der Kolk, LE; Wang, Q; Winqvist, R; Wu, AH; Yu, J-C; Zheng, W; Zheng, Y; Leary, J; Walker, L; Foretova, L; Fostira, F; Claes, KBM; Varesco, L; Moghadasi, S; Easton, DF; Spurdle, A; Devilee, P; Vrieling, H; Monteiro, ANA; Goldgar, DE; Carreira, A; Vreeswijk, MPG; Couch, FJ; for kConFab/AOCS Investigators; for NBCS Collaborators (2017-06-01)
      Breast cancer risks conferred by many germline missense variants in theBRCA1andBRCA2genes, often referred to as variants of uncertain significance (VUS), have not been established. In this study, associations between 19 ...
    • Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study. 

      Wright, LB; Schoemaker, MJ; Jones, ME; Ashworth, A; Swerdlow, AJ (2018-03-08)
      Preeclampsia and hyperemesis are pregnancy complications associated with altered sex hormone levels. Previous studies suggest preeclampsia may be associated with a decreased risk of subsequent breast cancer and hyperemesis ...
    • Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study. 

      Wright, LB; Schoemaker, MJ; Jones, ME; Ashworth, A; Swerdlow, AJ (2018-03-08)
      Preeclampsia and hyperemesis gravidarum are pregnancy complications associated with altered sex hormone levels. Previous studies suggest preeclampsia may be associated with a decreased risk of subsequent breast cancer and ...
    • Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study. 

      Swerdlow, AJ; Cooke, R; Beckers, D; Borgström, B; Butler, G; Carel, J-C; Cianfarani, S; Clayton, P; Coste, J; Deodati, A; Ecosse, E; Gausche, R; Giacomozzi, C; Hokken-Koelega, ACS; Khan, AJ; Kiess, W; Kuehni, CE; Mullis, P-E; Pfaffle, R; Sävendahl, L; Sommer, G; Thomas, M; Tidblad, A; Tollerfield, S; Van Eycken, L; Zandwijken, GRJ (2017-05-01)
      Context: Growth hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited. Objective: To examine cancer risks in relation to ...